Previous 10 | Next 10 |
2023-05-15 07:54:51 ET Alimera Sciences press release ( NASDAQ: ALIM ): Q1 GAAP EPS of -$0.71 misses by $0.19 . Revenue of $13.55M (+14.0% Y/Y) beats by $1.25M . For further details see: Alimera Sciences GAAP EPS of -$0.71 misses by $0.19, revenue of $13....
Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022 Global End User Demand Up 14% vs. First Quarter of 2022 Financial Results and Corporate Update Conference Call Cancelled ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. ...
2023-05-12 10:44:38 ET Major earnings expected before the bell on Monday include: Adamis Pharmaceuticals ( ADMP ) CV Sciences ( OTCQB:CVSI ) Sundial Growers ( SNDL ) Sunworks ( SUNW ) Workhorse Group ( WKHS ) For further details see: Notab...
ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report...
ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today ...
2023-04-03 12:32:21 ET Alimera Sciences ( NASDAQ: ALIM ) said it expanded an agreement with its distributor partner Horus Pharma for Iluvien to include Nordic countries The companies will expand their partnership beyond France, Belgium, Luxembourg and the Netherlands to boost ...
ATLANTA, April 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it...
2023-03-31 10:57:02 ET Alimera Sciences, Inc. (ALIM) Q4 2022 Earnings Conference Call March 31, 2023 09:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & CEO Russell Skibsted - SVP and CFO Conference Call ...
2023-03-31 08:04:56 ET Alimera Sciences press release ( NASDAQ: ALIM ): Q4 GAAP EPS of -$0.54 misses by $0.20 . Revenue of $14.03M (+0.5% Y/Y) misses by $0.59M . As of December 31, 2022, we had approximately $5.3M in cash and cash equivalents, a decrease of $0....
• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User Demand Increased 22% over 2021 to 9,266 Units • Strengthened Balance Sheet, Repurchased Stock and Extended Term Loan Facility ATLANTA, March 31, 2023 (GLOBE NEWSW...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Perficient, Inc. (NASDAQ:PRFT)'s sal...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc. (NASDAQ:ALIM)'...